EA201992410A3 - Ингибиторы тропомиозин-зависимых киназ (trk) - Google Patents

Ингибиторы тропомиозин-зависимых киназ (trk)

Info

Publication number
EA201992410A3
EA201992410A3 EA201992410A EA201992410A EA201992410A3 EA 201992410 A3 EA201992410 A3 EA 201992410A3 EA 201992410 A EA201992410 A EA 201992410A EA 201992410 A EA201992410 A EA 201992410A EA 201992410 A3 EA201992410 A3 EA 201992410A3
Authority
EA
Eurasian Patent Office
Prior art keywords
tropomyosin
dependent kinase
inhibitors
trk
trk inhibitors
Prior art date
Application number
EA201992410A
Other languages
English (en)
Other versions
EA201992410A2 (ru
Inventor
Джон Л. мл. Кейн
Глория Мэттьюз
Маркус Метц
Михаэль Коте
Цзиньюй Лю
Эндрю Сколт
Original Assignee
Джензим Корпорейшн
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Джензим Корпорейшн filed Critical Джензим Корпорейшн
Publication of EA201992410A2 publication Critical patent/EA201992410A2/ru
Publication of EA201992410A3 publication Critical patent/EA201992410A3/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/50—Organo-phosphines

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Ингибиторы тропомиозин-зависимых киназ (Trk-ингибиторы) являются соединениями-малыми молекулами, пригодными в лечении заболевания. Trk-ингибиторы можно применять в качестве фармацевтических средств и в фармацевтических композициях. Trk-ингибиторы пригодны в лечении воспалительных заболеваний, аутоиммунного заболевания, нарушений метаболизма в костной ткани и/или рака и особенно пригодны в лечении остеоартрита (OA), боли и связанной с OA боли. Trk-ингибиторы также пригодны для ингибирования тропомиозин-зависимой киназы A (TrkA), тропомиозин-зависимой киназы B (TrkB), тропомиозин-зависимой киназы C (TrkC) и/или c-FMS (клеточного рецептора для колониестимулирующего фактора-1 (CSF-1)).
EA201992410A 2014-08-22 2014-12-10 Ингибиторы тропомиозин-зависимых киназ (trk) EA201992410A3 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201462040750P 2014-08-22 2014-08-22

Publications (2)

Publication Number Publication Date
EA201992410A2 EA201992410A2 (ru) 2020-02-28
EA201992410A3 true EA201992410A3 (ru) 2020-05-31

Family

ID=69636691

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201992410A EA201992410A3 (ru) 2014-08-22 2014-12-10 Ингибиторы тропомиозин-зависимых киназ (trk)

Country Status (1)

Country Link
EA (1) EA201992410A3 (ru)

Also Published As

Publication number Publication date
EA201992410A2 (ru) 2020-02-28

Similar Documents

Publication Publication Date Title
EA201691196A1 (ru) Ингибиторы тропомиозин-зависимых киназ (trk)
EA201991399A1 (ru) Аминотриазолопиридиновые соединения и их применение в лечении рака
EA201890725A1 (ru) Агонисты фарнезоидного х-рецептора и их применение
EA201691151A1 (ru) Соединения для лечения пациентов с ros1-мутантными раковыми клетками
EA201790492A1 (ru) СОЕДИНЕНИЯ, КОТОРЫЕ ИНГИБИРУЮТ БЕЛОК Mcl-1
EA201792047A1 (ru) Новые соединения
EA201791018A1 (ru) Производные 6-амино-7-бицикло-7-деазапурина в качестве ингибиторов протеинкиназы
EA201691516A1 (ru) Дигидропирролопиридиновые ингибиторы ror-гамма
EA201790764A1 (ru) Новые соединения карбоновых кислот, подходящие для ингибирования микросомальной простагландин-e2-синтазы 1
EA201790078A1 (ru) Ингибиторы mnk и связанные с ними способы
EA201390772A1 (ru) Новые соли и полиморфные формы афатиниба
EA201590855A1 (ru) Соединения пирролопиримидина как ингибиторы киназ
EA201500394A1 (ru) Ингибиторы деметилаз гистонов
EA201792304A1 (ru) Комбинированная терапия для лечения рака
EA201891399A1 (ru) Бипиразолильные производные, пригодные для лечения аутоиммунных заболеваний
EA201290103A1 (ru) Гетероциклические соединения и их использование
EA201691853A1 (ru) Агонисты мускариновых рецепторов
EA201390682A1 (ru) Спирооксиндольные антагонисты mdm2
EA201790519A1 (ru) Терапевтические соединения в качестве ингибиторов рецептора орексина-1
JOP20200230A1 (ar) ناهضات ppar (مستقبل ناشر بيروكسيزوم منشط)، ومركبات، ومكونات أدوية، وطرق استعمالها
BR112016030730A8 (pt) composto
EA201891710A1 (ru) Терапевтические соединения
EA202190588A1 (ru) Гетероароматические соединения в качестве ингибиторов ванина
EA202191478A1 (ru) Гетероароматические соединения в качестве ингибиторов ванина
EA201790253A1 (ru) Ингибиторы альдостеронсинтазы